onestepahead asked for suggestions to help get ove
Post# of 148279
(Total Views: 786)
Posted On: 08/17/2022 9:28:38 PM
Re: onestepahead #127809
onestepahead asked for suggestions to help get over Covid more quickly. HHIGambler suggested Tollovid (via suggestion from misiu) to strengthen the immune system. I have not had Covid and don't have any suggestions, however, I keep Tollovid on hand in case I get it.
I just finished reading an article that discussed three drugs which probably won't help. In case someone suggests that you take one of these, I'll post some excerpts and the link below in case you want to read the entire article. Note that the patients in this study were obese, so it may not necessarily apply to those who are not obese.
I hope we can get back on track with Covid trials - it appears that field is still wide open.
Early treatment with three repurposed drugs -- metformin, ivermectin, or fluvoxamine -- did not prevent severe outcomes from COVID-19 in high-risk patients, according to a phase III randomized trial.
Among over 1,300 patients with overweight or obesity, the adjusted odds ratio for a primary event, including hypoxemia, an emergency department (ED) visit, hospitalization, or death, was 0.84 (95% CI 0.66-1.09, P=0.19) with metformin, 1.05 (95% CI 0.76-1.45, P=0.78) with ivermectin, and 0.94 (95% CI 0.66-1.36, P=0.75) with fluvoxamine, compared with placebo, reported Carolyn T. Bramante, MD, MPH, of the University of Minnesota in Minneapolis, and colleagues in the New England Journal of Medicine.
In prespecified secondary analyses, the adjusted odds ratios for an ED visit/hospitalization/death and hospitalization/death with the three drugs were:
0.58 (95% CI 0.35-0.94) and 0.47 (95% CI 0.20-1.11) with metformin
1.39 (95% CI 0.72-2.69) and 0.73 (95% CI 0.19-2.77) with ivermectin
1.17 (95% CI 0.57-2.40) and 1.11 (95% CI 0.33-3.76) with fluvoxamine
While a "possible benefit for the prevention of the more severe components of the primary endpoint ... was shown for metformin ... this finding was a prespecified secondary endpoint and thus cannot be considered to be definitive pending the results of other trials," Bramante and team wrote.
In an accompanying editorial, Salim S. Abdool Karim, MB, ChB, PhD, and Nikita Devnarain, PhD, of the Mailman School of Public Health at Columbia University in New York City, noted that doctors are doing more harm than good by using drugs that don't work, asking, "How much evidence of nonefficacy is enough?"
"Prescribing nonefficacious treatments is not a neutral or harmless option," they wrote, pointing out that not only does this practice keep patients from getting the right treatment, it also can lead to potential side effects and drug shortages for patients who need the drugs for other illnesses.
"Hence, it is important to have reliable evidence of nonefficacy and to have journals publish such studies," they continued. "It is also important that multiple rigorous randomized, controlled trials be performed to provide unequivocal evidence on the efficacy of new treatments."
"In keeping with evidence-based medical practice, patients with COVID-19 must be treated with efficacious medications; they deserve nothing less," they concluded.
For this double-blind, placebo-controlled study, which was conducted from Dec. 30, 2020 to Jan. 28, 2022, Bramante and colleagues included 1,323 patients (median age 46, 56% women) from six institutions. Six percent of the women were pregnant, and 52.2% of the overall group were vaccinated.
The primary composite endpoint was hypoxemia (≤93% oxygen saturation on home oximetry), an ED visit, hospitalization, or death.
https://www.medpagetoday.com/infectiousdiseas...definition
I just finished reading an article that discussed three drugs which probably won't help. In case someone suggests that you take one of these, I'll post some excerpts and the link below in case you want to read the entire article. Note that the patients in this study were obese, so it may not necessarily apply to those who are not obese.
I hope we can get back on track with Covid trials - it appears that field is still wide open.
Early treatment with three repurposed drugs -- metformin, ivermectin, or fluvoxamine -- did not prevent severe outcomes from COVID-19 in high-risk patients, according to a phase III randomized trial.
Among over 1,300 patients with overweight or obesity, the adjusted odds ratio for a primary event, including hypoxemia, an emergency department (ED) visit, hospitalization, or death, was 0.84 (95% CI 0.66-1.09, P=0.19) with metformin, 1.05 (95% CI 0.76-1.45, P=0.78) with ivermectin, and 0.94 (95% CI 0.66-1.36, P=0.75) with fluvoxamine, compared with placebo, reported Carolyn T. Bramante, MD, MPH, of the University of Minnesota in Minneapolis, and colleagues in the New England Journal of Medicine.
In prespecified secondary analyses, the adjusted odds ratios for an ED visit/hospitalization/death and hospitalization/death with the three drugs were:
0.58 (95% CI 0.35-0.94) and 0.47 (95% CI 0.20-1.11) with metformin
1.39 (95% CI 0.72-2.69) and 0.73 (95% CI 0.19-2.77) with ivermectin
1.17 (95% CI 0.57-2.40) and 1.11 (95% CI 0.33-3.76) with fluvoxamine
While a "possible benefit for the prevention of the more severe components of the primary endpoint ... was shown for metformin ... this finding was a prespecified secondary endpoint and thus cannot be considered to be definitive pending the results of other trials," Bramante and team wrote.
In an accompanying editorial, Salim S. Abdool Karim, MB, ChB, PhD, and Nikita Devnarain, PhD, of the Mailman School of Public Health at Columbia University in New York City, noted that doctors are doing more harm than good by using drugs that don't work, asking, "How much evidence of nonefficacy is enough?"
"Prescribing nonefficacious treatments is not a neutral or harmless option," they wrote, pointing out that not only does this practice keep patients from getting the right treatment, it also can lead to potential side effects and drug shortages for patients who need the drugs for other illnesses.
"Hence, it is important to have reliable evidence of nonefficacy and to have journals publish such studies," they continued. "It is also important that multiple rigorous randomized, controlled trials be performed to provide unequivocal evidence on the efficacy of new treatments."
"In keeping with evidence-based medical practice, patients with COVID-19 must be treated with efficacious medications; they deserve nothing less," they concluded.
For this double-blind, placebo-controlled study, which was conducted from Dec. 30, 2020 to Jan. 28, 2022, Bramante and colleagues included 1,323 patients (median age 46, 56% women) from six institutions. Six percent of the women were pregnant, and 52.2% of the overall group were vaccinated.
The primary composite endpoint was hypoxemia (≤93% oxygen saturation on home oximetry), an ED visit, hospitalization, or death.
https://www.medpagetoday.com/infectiousdiseas...definition
(2)
(1)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼